For Institutions
- Corporate Services
- Developers
Download
Help
About

Markets

Information

Academy

Options & Futures

IPO Subscription

Structured Products

Investment Wiki

Affiliate Program

Promotions

EN

English

简体中文

繁體中文

繁體中文（廣東話）Posts & comments will be shown in Cantonese

Search...

Quote List Quote List

Tibet Dongcai CSI Hugangshen Innovative Drugs Industry ETF(159622.SZ)

© 2026 Longbridge｜Disclaimer

Event Tracking

Jan2

Sino-Pharm Group Obtains Approval for Clinical Trials of Inhaled Nintedanib in China

11:49

Dec31

China Biopharma Initiates Phase III Clinical Trial of TDI01 for Idiopathic Pulmonary Fibrosis

04:31

Dec30

Konka Biotech Develops and Approves Global First Tumor Immune Bispecific Antibody Camrelizumab

23:16

Dec29

Ping An Good Doctor Collaborates with Wuhan No.3 Hospital to Launch 'Direct Settlement' Service

19:11

Stone Pharmaceutical Group Secures Approval for Multiple Drug Trials in China

12:33

Jade Pharmaceutical's SYH2072 Receives Approval for Clinical Trials from NMPA

10:32